By Dave Sebastian

Pfizer Inc. has agreed to buy shares it didn't already own in Trillium Therapeutics Inc., a company focused on developing therapies for cancer treatment, for an implied equity value of $2.26 billion.

The companies on Monday said Pfizer is paying $18.50 a share in cash. Trilium shares closed at $6.09 on Nasdaq on Friday.

The deal would boost Pfizer's oncology category with the addition of immuno-therapeutics for hematological malignancies, they said.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

08-23-21 0713ET